InsiderClue
Stocks · Health care · Pharmaceutical Preparations

SPRUCE BIOSCIENCES, INC.

SPRB Clue Score34
United States Fiscal year ends December CIK 0001683553
$44.05 -3.27% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $44.05 +750.39% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 9 Oct 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Operating income−13.1Net income−13.1Fiscal year 2020Operating income−29.4Net income−29.5Fiscal year 2021Operating income−42.1Net income−42.3EPS, diluted−1.81Fiscal year 2022Revenue0.0Operating income−47.3Net income−46.2EPS, diluted−1.96Fiscal year 2023Revenue10.1Operating income−52.0Net income−47.9EPS, diluted−1.24Fiscal year 2024Revenue4.9 −51.3%Operating income−56.2Net income−53.0EPS, diluted−96.40Fiscal year 2025Revenue0.0 −100.0%Operating income−36.5Net income−39.0EPS, diluted−50.83
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a 0.0 10.1 4.9 0.0
Growth −51.3% −100.0%
Operating income −13.1 −29.4 −42.1 −47.3 −52.0 −56.2 −36.5
Net income −13.1 −29.5 −42.3 −46.2 −47.9 −53.0 −39.0
Growth
EPS, diluted n/a n/a −1.81 −1.96 −1.24 −96.40 −50.83

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Operating margin−515.3%Net margin−475.0%Free cash flow margin−329.9%Fiscal year 2024Operating margin−1,143.4%Net margin−1,079.9%Free cash flow margin−1,139.6%Fiscal year 2025
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −515.3% −1,143.4% n/a
Net margin n/a n/a n/a n/a −475.0% −1,079.9% n/a
Free cash flow margin n/a n/a n/a n/a −329.9% −1,139.6% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−12.6Capital expenditure−0.0Free cash flow−12.6Fiscal year 2020Operating cash flow−27.5Capital expenditure−0.1Free cash flow−27.6Fiscal year 2021Operating cash flow−35.9Capital expenditure−0.1Free cash flow−36.0Fiscal year 2022Operating cash flow−41.7Capital expenditure−0.0Free cash flow−41.7Fiscal year 2023Operating cash flow−33.3Capital expenditure−0.0Free cash flow−33.3Fiscal year 2024Operating cash flow−56.0Capital expenditure0.0Free cash flow−56.0Fiscal year 2025Operating cash flow−33.3
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −12.6 −27.5 −35.9 −41.7 −33.3 −56.0 −33.3
Capital expenditure −0.0 −0.1 −0.1 −0.0 −0.0 0.0 n/a
Free cash flow −12.6 −27.6 −36.0 −41.7 −33.3 −56.0 n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2019Cash3.9Total debt4.4Net cash (debt)−0.5Shareholders’ equity−30.6Fiscal year 2020Cash157.2Total debt4.5Net cash (debt)152.7Shareholders’ equity149.4Debt to equity0.03Fiscal year 2021Cash42.7Total debt4.9Net cash (debt)37.9Shareholders’ equity111.4Debt to equity0.04Fiscal year 2022Cash24.5Total debt4.9Net cash (debt)19.6Shareholders’ equity68.5Debt to equity0.07Fiscal year 2023Cash96.3Total debt3.3Net cash (debt)93.0Shareholders’ equity76.5Debt to equity0.04Fiscal year 2024Cash38.8Total debt1.7Net cash (debt)37.0Shareholders’ equity28.8Debt to equity0.06Fiscal year 2025Cash48.9Total debt0.0Net cash (debt)48.9Shareholders’ equity42.5Debt to equity0.00
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 3.9 157.2 42.7 24.5 96.3 38.8 48.9
Total debt 4.4 4.5 4.9 4.9 3.3 1.7 0.0
Net cash (debt) −0.5 152.7 37.9 19.6 93.0 37.0 48.9
Shareholders’ equity −30.6 149.4 111.4 68.5 76.5 28.8 42.5
Debt to equity n/a 0.03 0.04 0.07 0.04 0.06 0.00

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a n/a 0.0 10.1 4.9 0.0
Growth −51.3% −100.0%
10.8 23.9 30.7 35.2 49.4 46.4 19.5
2.3 5.6 11.4 12.1 12.7 14.6 17.0
−13.1 −29.4 −42.1 −47.3 −52.0 −56.2 −36.5
Growth
0.0 0.0 0.0 0.0 0.0 0.0 0.0
−13.1 −29.5 −42.3 −46.2 −47.9 −53.0 −39.0
Growth
Per share
n/a n/a −1.81 −1.96 −1.24 −96.40 −50.83
n/a n/a −1.81 −1.96 −1.24 −96.40 −50.83
Growth
n/a n/a 23.4 23.5 38.5 0.6 0.8
n/a n/a 23.4 23.5 38.5 0.6 0.8
Growth +0.7% +63.7% −98.6% +39.3%

† The diluted share count jumps at 2023 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.